Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia

@article{Fink2018PharmacologicIT,
  title={Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia},
  author={H. Fink and E. Jutkowitz and J. McCarten and L. Hemmy and M. Butler and Heather Davila and E. Ratner and Collin Calvert and T. Barclay and M. Brasure and Victoria A. Nelson and R. Kane},
  journal={Annals of Internal Medicine},
  year={2018},
  volume={168},
  pages={39-51}
}
Dementia is a clinical syndrome in which an acquired cognitive deficit interferes with a person's independence in daily activities (1). It adversely affects patient quality of life, burdens caregivers, increases institutionalization, and is costly to families and society (2). Alzheimer disease is the most common cause of dementia, although differentiation between when Alzheimer disease is present in isolation and when it is combined with another cause of dementia may not be possible in clinical… Expand
Mild Cognitive Impairment in Clinical Practice: A Review Article
TLDR
Lifestyle modification, such as aerobic exercise, is an approved modality to preserve cognitive ability and decrease the rate of progression to dementia, as well as being recommended for frailty prevention. Expand
Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults.
TLDR
Investigation of the associations of statin use with cognitive decline and incident dementia among older adults found statin therapy was not associated with dementia, MCI, or declines in individual cognition domains. Expand
Cognitive decline in older adults: applying multiple perspectives to develop novel prevention strategies
Cognitive decline among older adults encompasses the range of subclinical decline, mild cognitive impairment (MCI), and Alzheimer-type dementia. In 2015, 47 million people worldwide were estimated toExpand
Mild cognitive impairment in primary care: a clinical review
TLDR
This review discusses the case of a patient with MCI and provides an evidence-based framework for assessment, early recognition and management of MCI while addressing associated risk factors, neuropsychiatric symptoms and prognosis. Expand
Reconsidering the overdiagnosis of mild cognitive impairment for dementia prevention among adults aged ≥80 years
TLDR
It is necessary to increase patients’ health literacy, which requires medical professionals to provide them with appropriate evidence-based information, and it is important to provide psychological support to people who have been diagnosed. Expand
Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer’s Disease
TLDR
Insight is provided into the role of non-pharmacologic interventions in the modulation of AD pathology, which may offer the benefit of improving quality of life by reducing cognitive decline and incident AD. Expand
Anti-dementia medications: Fighting a losing battle?
TLDR
The treatment of AD remains a challenge, with a special focus on behavioral symptoms, and interventions that could delay or prevent dementia onset in some subjects are focused on minimizing modifiable risk factors and maximizing protective factors. Expand
A Multifactor Approach to Mild Cognitive Impairment
TLDR
Different conceptions of MCI are reviewed, the diagnosis and prognostication ofMCI, and presently available management approaches for this condition are reviewed. Expand
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
TLDR
Emerging optimism for improved outcomes in AD stems from a focus on preventive interventions in midlife and timely, biomarker‐confirmed diagnosis at early signs of cognitive deficits, which is particularly important for optimizing patient care and enabling the appropriate use of anticipated DMTs. Expand
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
TLDR
This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 141 REFERENCES
Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis.
TLDR
Diabetes increased the risk of conversion to dementia and other prognostic factors that are potentially manageable are prediabetes and the metabolic syndrome, neuropsychiatric symptoms, and low dietary folate. Expand
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
TLDR
The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Expand
Mild cognitive impairment as a diagnostic entity
TLDR
It is suggested that the diagnosis of mild cognitive impairment can be made in a fashion similar to the clinical diagnoses of dementia and AD, and an algorithm is presented to assist the clinician in identifying subjects and subclassifying them into the various types of MCI. Expand
Treatment for mild cognitive impairment: systematic review
TLDR
Preliminary evidence suggests that good-quality RCTs evaluating the effects of any intervention for MCI should include trials of psychological group interventions and piribedil, and there was no replicated evidence that any intervention was effective. Expand
Vitamin E and donepezil for the treatment of mild cognitive impairment.
TLDR
Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures. Expand
Preventing Alzheimer's disease and cognitive decline.
TLDR
The current research on the list of putative risk or protective factors is largely inadequate to confidently assess their association with AD or cognitive decline, and further research that addresses the limitations of existing studies is needed to be able to make recommendations on interventions. Expand
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
TLDR
Raloxifene at a dose of 120 mg/day, but not 60 mg/days, resulted in reduced risk of cognitive impairment in postmenopausal women. Expand
Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association
TLDR
Judicious treatment of hypertension, taking into account goals of care and individual characteristics (eg, age and comorbidities), seems justified to safeguard vascular health and, as a consequence, brain health. Expand
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
TLDR
The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted and the rivastigmine treatment was not associated with any significant safety concerns. Expand
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.
TLDR
A larger trial seems warranted to evaluate the efficacy and cognitive safety of metformin in prodromal AD, and changes in total recall of the Selective Reminding Test and the score of the Alzheimer's Disease Assessment Scale-cognitive subscale were not significant. Expand
...
1
2
3
4
5
...